HPLC-MS/MS method for the simultaneous determination of clopidogrel, its carboxylic acid metabolite and derivatized isomers of thiol metabolite in clinical samples

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 911, Issue , 2012, Pages 105-112

  Karaźniewicz Łada, Marta ^a   Danielak, Dorota ^a   Tezyk, Artur ^a   zaba, Czesław ^a   Tuffal, Gilles ^b   Główka, Franciszek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b SANOFI   (France)

Author keywords

Clopidogrel; HPLC MS MS resolution; Pharmacokinetics; Thiol metabolite active isomer; Validation

Indexed keywords

ANALYTES; AUTOSAMPLERS; CALIBRATION CURVES; CARBOXYLIC ACID DERIVATIVES; CLINICAL SAMPLES; CLOPIDOGREL; GRADIENT ELUTION; HPLC-MS/MS; HUMAN PLASMAS; INTER-ASSAY PRECISION; INTERNAL STANDARDS; LOWER LIMIT OF QUANTITATIONS; PHARMACOKINETIC STUDIES; PIROXICAM; PLASMA SAMPLES; PROTEIN PRECIPITATION; RELATIVE ERRORS; RELATIVE STANDARD DEVIATIONS; ROOM TEMPERATURE; SIMULTANEOUS DETERMINATIONS; VALIDATION;

ACETONITRILE; BIOMOLECULES; ELECTROSPRAY IONIZATION; FORMIC ACID; METABOLITES; PATIENT MONITORING; PHARMACOKINETICS; PLASMAS;

ISOMERS;

ACETONITRILE; CARBOXYLIC ACID DERIVATIVE; CLOPIDOGREL; THIOL;

AGED; ARTICLE; CLINICAL ARTICLE; DRUG DETERMINATION; ELECTROSPRAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; MALE; MASS SPECTROMETRY; PRECIPITATION; PRIORITY JOURNAL;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; ISOMERISM; LINEAR MODELS; MALE; REPRODUCIBILITY OF RESULTS; SULFHYDRYL COMPOUNDS; TANDEM MASS SPECTROMETRY; TICLOPIDINE;

EID: 84870477806     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.11.005     Document Type: Article

References (22)

1. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., Pascal M., Herbert J.M., Maffrand J.P., Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 2002, 30:1288-1295.
2. Jarvis B., Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000, 60:347-377.
3. De Miguel A., Ibanez B., Badimon J.J. Clinical implications of clopidogrel resistance. Thromb. Haemost. 2008, 100:196-203.
4. Karaźniewicz Łada M., Danielak D., Główka F. Genetic and non-genetic factors affecting the response to clopidogrel therapy. Expert Opin. Pharmacother. 2012, 13:663-683.
5. Taubert D., Beckerath N., Grimberg G., Lazar A., Jung N., Goeser T., Kastrati A., Schömig A., Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther. 2006, 80:486-501.
6. Farid N.A., Kurihara A., Wrighton S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010, 50:126-142.
7. Mani H., Toennes S.W., Linnemann B., Urbanek D.A., Schwonberg J., Kauert G.F., Lindhoff-Last.E. Determination of clopidogrel main metabolite in plasma: a useful tool for monitoring therapy?. Ther. Drug Monit. 2008, 30:84-89.
8. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., Ikeda T., Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 2010, 38:92-99.
9. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., Walker J.R., Antman E.M., Macias W., Braunwald E., Sabatine M.S. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360:354-362.
10. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Meneveau N., Steg P.G., Ferrieres J., Danchin N., Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009, 360:363-375.
11. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 2000, 84:891-896.
12. Tuffal G., Roy S., Lavisse M., Brasseur D., Schofield J., Delesque Touchard N., Savi P., Bremond N., Rouchon M.C., Hurbin F., Sultan E. An improved method for specific and quantitative determination of the clopidogrel active metabolite isomers in human plasma. Thromb. Haemost. 2011, 105:696-705.
13. Takahashi M., Pang H., Kawabata K., Farid N.A., Kurihara A. Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 2008, 48:1219-1224.
14. Delavenne X., Basset T., Zufferey P., Malouk N., Laporte S., Mismetti P. Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. J. Sep. Sci. 2010, 33:1968-1972.
15. Peer C.J., Spencer S.D., VanDenBerg D.A., Pacanowski M.A., Horenstein R.B., Figg W.D. A sensitive and rapid ultra HPLC-MS/MS method for the simultaneous detection of clopidogrel and its derivatized active thiol metabolite in human plasma. J. Chromatogr. B 2012, 880:132-139.
16. Patel N.K., Subbaiah G., Shah H., Mohan M., Shrivastav P.S. Rapid LC-ESI-MS-MS method for the simultaneous determination of clopidogrel and its carboxylic acid metabolite in human plasma. J. Chromatogr. Sci. 2008, 46:867-875.
17. Silvestro L., Gheorghe M., Iordachescu A., Ciuca V., Tudoroniu A., Rizea Savu S., Tarcomnicu I. Development and validation of an HPLC-MS/MS method to quantify clopidogrel acyl glucuronide, clopidogrel acid metabolite, and clopidogrel in plasma samples avoiding analyte back-conversion. Anal. Bioanal. Chem. 2011, 401:1023-1034.
18. Taubert D., Kastrati A., Harlfinger S., Gorchakova O., Lazar A., von Beckerath N., Schömig A., Schömig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 2004, 92:311-316.
19. Van Loco J., Elskens M., Croux C., Beernaert H. Linearity of calibration curves: use and misuse of the correlation coefficient. Accredit. Qual. Assur. 2002, 7:281-285.
20. <> (accessed 16.07.12). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
21. Gong I.Y., Crown N., Suen C.M., Schwarz U.I., Dresser G.K., Knauer M.J., Sugiyama D., DeGorter M.K., Woolsey S., Tirona R.G., Kim R.B. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Eur. Heart J. 2012, 10.1093/eurheartj/ehs042.
22. Nirogi R.V.S., Kandikere V.N., Mudigonda K. Effect of food on bioavailability of a single oral dose of clopidogrel in healthy male subjects. Arzneimittelforschung. 2006, 56:735-739.